Mobile

A randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching place...

Mise à jour : Il y a 5 ans
Référence : EUCTR2008-000498-40

A randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line rituximabchemotherapy

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare disease-free survival (DFS) in poor risk patients with DLBCL after achieving CR following first-line R-CHOP who receive RAD001 versus patients who receive matching placebo.

Critère d'inclusion

  • Diffuse large B-cell lymphoma

Liens